Literature DB >> 29378386

Stachydrine ameliorates carbon tetrachloride-induced hepatic fibrosis by inhibiting inflammation, oxidative stress and regulating MMPs/TIMPs system in rats.

Jinlin Zhang1, Aihua Yang2, Yu Wu3, Wei Guan4, Biao Xiong4, Xiaoqing Peng5, Xiaojin Wei1, Chang Chen4, Zhaoguo Liu6.   

Abstract

Inflammation and oxidative stress are two crucial factors mediating liver fibrosis. Stachydrine (STA) is a naturally occurring compound extracted from a medicinal plant Leonuru heterophyllus, which can inhibit the proliferation and induce the apoptosis of breast cancer cells, relieve high glucose-induced endothelial cell senescence and isoproterenol-induced cardiac hypertrophy, and exert antitumor effects. However, its roles in hepatic fibrosis remain largely unknown. We aimed to evaluate the effect of STA on carbon tetrachloride (CCl4)-induced hepatic fibrosis in rats and to elucidate the possible mechanisms. STA alleviated the pathological changes caused by CCl4 injection in livers compared to the normal liver. Hematoxylin-eosin staining further showed that STA treatment remarkably improved the liver histology, as evidenced by mitigated hepatic steatosis, necrosis, and fibrotic septa. STA reduced the liver/body weight ratio and the serum levels of aminotransferase, aspartate aminotransferase and alkaline phosphatase. It also significantly decreased collagen deposition and hydroxyproline level. Both mRNA and protein levels of α-SMA, α1(I)-procollagen and fibronectin were decreased by STA compared to those of the model group. STA significantly inhibited the expressions of inflammatory factors interleukin-6 (IL-6), IL-8, IL-1β, tumor necrosis factor-α, inducible nitric oxide synthase and cyclooxygenase-2. It suppressed oxidative stress by decreasing malondialdehyde level as well as increasing glutathione level and enzymatic activities of superoxide dismutase, catalase, glutathione reductase and glutathione peroxidase. STA also significantly increased the protein expressions of tissue inhibitor of metallopeptidase-1 (TIMP-1) and TIMP-2 but decreased those of matrix metalloproteinase-2 (MMP-2) and MMP-9, indicating excessive basement membrane in the fibrotic liver. Collectively, STA has potent protective effects on the liver, with therapeutic implication for liver fibrosis.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Inflammation; Liver fibrosis; Matrix metalloproteinase; Oxidative stress; Stachydrine

Mesh:

Substances:

Year:  2017        PMID: 29378386     DOI: 10.1016/j.biopha.2017.11.117

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  11 in total

1.  Stachydrine alleviates lipid-induced skeletal muscle insulin resistance via AMPK/HO-1-mediated suppression of inflammation and endoplasmic reticulum stress.

Authors:  T W Jung; H Kim; S Y Park; W Cho; H Oh; H J Lee; A M Abd El-Aty; A Hacimuftuoglu; J H Jeong
Journal:  J Endocrinol Invest       Date:  2022-07-14       Impact factor: 5.467

2.  Integrative Analysis of Metabolomic and Transcriptomic Data Reveals the Antioxidant Potential of Dietary Lutein in Chickens.

Authors:  Tuanhui Ren; Wujian Lin; Shizi He; Xiuxian Yang; Mingjian Xian; Zihao Zhang; Wen Luo; Qinghua Nie; Xiquan Zhang
Journal:  Front Vet Sci       Date:  2022-06-23

Review 3.  Tumor microenvironment: a prospective target of natural alkaloids for cancer treatment.

Authors:  Yanming Luo; Shuangshuang Yin; Jia Lu; Shiyue Zhou; Yingying Shao; Xiaomei Bao; Tao Wang; Yuling Qiu; Haiyang Yu
Journal:  Cancer Cell Int       Date:  2021-07-20       Impact factor: 5.722

4.  Metabolomics profiling of xenobiotics in elite athletes: relevance to supplement consumption.

Authors:  Fatima Al-Khelaifi; Ilhame Diboun; Francesco Donati; Francesco Botrè; Mohammed Alsayrafi; Costas Georgakopoulos; Noha A Yousri; Karsten Suhre; Mohamed A Elrayess
Journal:  J Int Soc Sports Nutr       Date:  2018-09-27       Impact factor: 5.150

5.  Stachydrine Ameliorates Cardiac Fibrosis Through Inhibition of Angiotensin II/Transformation Growth Factor β1 Fibrogenic Axis.

Authors:  Xiao Liu; Xiaoli Shan; Huihua Chen; Zan Li; Pei Zhao; Chen Zhang; Wei Guo; Ming Xu; Rong Lu
Journal:  Front Pharmacol       Date:  2019-05-22       Impact factor: 5.810

6.  Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.

Authors:  Jiahong Meng; Chenhe Zhou; Wenkan Zhang; Wei Wang; Bin He; Bin Hu; Guangyao Jiang; Yangxin Wang; Jianqiao Hong; Sihao Li; Jiamin He; Shigui Yan; Weiqi Yan
Journal:  J Cell Mol Med       Date:  2019-07-21       Impact factor: 5.310

7.  Celastrol exerts anti-inflammatory effect in liver fibrosis via activation of AMPK-SIRT3 signalling.

Authors:  Yuqin Wang; Chunling Li; Jingya Gu; Chang Chen; Jiaxin Duanmu; Jing Miao; Wenjuan Yao; Jinhua Tao; Mengjue Tu; Biao Xiong; Lingling Zhao; Zhaoguo Liu
Journal:  J Cell Mol Med       Date:  2019-11-19       Impact factor: 5.310

8.  Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity.

Authors:  Gabriella Sistilli; Veronika Kalendova; Tomas Cajka; Illaria Irodenko; Kristina Bardova; Marina Oseeva; Petr Zacek; Petra Kroupova; Olga Horakova; Karoline Lackner; Amalia Gastaldelli; Ondrej Kuda; Jan Kopecky; Martin Rossmeisl
Journal:  Nutrients       Date:  2021-01-29       Impact factor: 5.717

9.  Inhibitor 1 of Protein Phosphatase 1 Regulates Ca2+/Calmodulin-Dependent Protein Kinase II to Alleviate Oxidative Stress in Hypoxia-Reoxygenation Injury of Cardiomyocytes.

Authors:  Huiqin Luo; Shu Song; Yun Chen; Mengting Xu; Linlin Sun; Guoliang Meng; Wei Zhang
Journal:  Oxid Med Cell Longev       Date:  2019-12-07       Impact factor: 6.543

10.  Withaferin A Exerts Preventive Effect on Liver Fibrosis through Oxidative Stress Inhibition in a Sirtuin 3-Dependent Manner.

Authors:  Jingya Gu; Chang Chen; Jue Wang; Tingting Chen; Wenjuan Yao; Tingdong Yan; Zhaoguo Liu
Journal:  Oxid Med Cell Longev       Date:  2020-09-24       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.